Clinical trial · Observational
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit.
NCT04965870CI-TRIAL-00056926RETRO-TAScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trifluridine/Tipiracil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
- description
- PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first.
Secondary outcomes (3)
- measure
- Overall Survival
- timeFrame
- Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
- description
- Overall survival is defined as the time interval from initiation of treatment to the date of death due to any cause.
- measure
- Progression Free Survival rate at 6 and 8 months
- timeFrame
- Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Histologically confirmed metastatic colorectal cancer * Available data on previous chemotherapy lines Exclusion Criteria: No exclusion criteria have been established for this observational and retrospective study.
References
Publications (0)
Data not yet available
No reference posted for this study.